Calcium, Blueprint Medicines, and Genentech
GAVRETO HCP Website: Look to Push RET Back
For far too long, RET was an overwhelming force of oncogenic growth in metastatic non–small cell lung cancer and advanced thyroid cancers. And before a RET-targeted therapy like GAVRETO came along, HCPs had no means to stand up to these biomarker-driven cancers. But now HCPs can push RET back like never before. Our campaign embodies this concept.
Calcium Team Members:
Steven Michaelson, Founder & Chairman
Chris Watson, Group Creative Director
Oliver Murphy, VP, Group Account Director
Jon Rea, VP, Associate Creative Director, Art
Anastasia Shamin, VP, Associate Creative Director, Copy
Charlie Peterson, Account Supervisor
Ashley Woodward, Group Art Supervisor
Avery Sohn, Senior Art Director
Casey Voss, Group Copy Supervisor
Patty Wilcox, Copy Supervisor
Mitchell Schuman, Account Executive
Mike Brindisi, Senior Project Manager
Blueprint Medicines Team Members:
Natalie Wills, Associate Director, Pralsetinib
Greg Veneziano Jr., Head of U.S. Precision Medicine
